Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

被引：1

作者：

Kewan, Tariq ^{[1
,2
]}

Bewersdorf, Jan Philipp ^{[3
]}

Blaha, Ondrej ^{[4
]}

Stahl, Maximilian ^{[5
]}

Al Ali, Najla H. ^{[6
]}

DeZern, Amy E. ^{[7
]}

Sekeres, Mikkael A. ^{[8
]}

Carraway, Hetty E. ^{[9
]}

Desai, Pinkal ^{[10
]}

Griffiths, Elizabeth A. ^{[11
]}

Stein, Eytan M. ^{[12
]}

Brunner, Andrew M. ^{[13
]}

Amaya, Maria L. ^{[14
]}

Zeidner, Joshua F. ^{[15
]}

Savona, Michael R. ^{[16
]}

Stempel, Jessica M. ^{[17
]}

Chandhok, Namrata Sonia ^{[18
]}

Cochran, Hunter ^{[19
]}

Ramaswamy, Rahul ^{[19
]}

Singh, Abhay ^{[20
]}

Roboz, Gail J. ^{[21
,22
]}

Rolles, Benjamin ^{[23
]}

Wang, Eunice S. ^{[24
]}

Harris, Amyah C. ^{[25
]}

Shallis, Rory M. ^{[1
,2
]}

Xie, Zhuoer ^{[26
]}

Padron, Eric ^{[5
,6
]}

Maciejewski, Jaroslaw P. ^{[27
]}

Della Porta, Matteo Giovanni ^{[28
]}

Komrokji, Rami S. ^{[5
,6
]}

Sallman, David A. ^{[29
]}

Zeidan, Amer M. ^{[17
]}

机构：

[1] Yale Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[5] Dana Farber Inst, Boston, MA USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[7] Johns Hopkins Univ, Sidney Kimmel CCC, Baltimore, MD USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Cleveland Clin, Leukemia Program, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[10] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[11] Roswell Pk Comprehens Canc Ctr, Dept Med, Leukemia Serv, Buffalo, NY USA

[12] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA

[13] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA USA

[14] Univ Colorado, Div Hematol, Aurora, CO USA

[15] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[16] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA

[17] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol,Yale Canc Ctr, New Haven, CT USA

[18] Univ Miami, Miami, FL USA

[19] Washington Univ, St Louis, MO USA

[20] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH USA

[21] Weill Cornell Med, New York, NY USA

[22] New York Presbyterian Hosp, New York, NY USA

[23] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA USA

[24] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY USA

[25] Dana Farber Canc Inst, Boston, MA USA

[26] H Lee Moffitt Canc Inst, Tampa, FL USA

[27] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA

[28] IRCCS, Humanitas Clin & Res Ctr, Rozzano, Italy

[29] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-186875

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 23 条

[21] Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial
Mossner, Maximilian
Jann, Johann Christoph
Launiger-Loersch, Evi
Nowak, Daniel
Platzbecker, Uwe
Giagounidis, Aristoteles
Goetze, Katharina
Letsch, Anne
Haase, Detlef
Shirneshan, Katayoon
Schlenk, Richard F.
Haferlach, Torsten
Bug, Gesine
Luebbert, Michael
Ganser, Arnold
Nowak, Verena
Pressler, Jovita
Oblaender, Julia
Fey, Stephanie
Mueller, Nadine
Metzgeroth, Georgia
Hofmann, Wolf-Karsten
Germing, Ulrich
Nolte, Florian
BLOOD, 2014, 124 (21)
[22] Impact of TP53 mutations on the clinical course in patients with MDS and isolated deletion 5(q) treated with Lenalidomid: results from the prospective Le-Mon-5 trial
Mossner, M.
Jann, J. -C
Launinger-Loersch, E.
Nowak, D.
Platzbecker, U.
Giagounidis, A.
Goetze, K.
Letsch, A.
Haase, D.
Shirneshan, K.
Schlenk, R. F.
Kohlmann, A.
Haferlach, T.
Bug, G.
Luebbert, M.
Ganser, A.
Nowak, V
Pressler, J.
Oblaender, J.
Fey, S.
Mueller, N.
Metzgeroth, G.
Hofmann, W. -K
Germing, U.
Nolte, F.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 233 - 233
[23] Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
Mukherjee, Sudipto
Savill, Kristin M.
Gajra, Ajeet
Gentile, Danielle
Falkenstein, Angelica
Miller, Talia
Laney, JaLyna
McBride, Ali
BLOOD, 2022, 140 : 10998 - 11000

← 1 2 3 →